SCHEMBL21991853

SCHEMBL21991853

COC(=O)C(C)C(C)Oc1ccc(OCc2ccc(Cl)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.55
MAOA P21397 3/20 0.55
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
NR4A2 P43354 1/20 0.52
FFAR1 O14842 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
APP P05067 1/20 0.47
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LTA4H P09960 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21991832 0.88 L3MBTL1 (0.57) MAOBMAOANPC1RAB9ANR4A2
SCHEMBL21991855 0.88 MAOB (0.53) MAOBMAOANPC1RAB9ANR4A2
SCHEMBL21991494 0.87 GAA (0.44) RAB9AALDH1A1MAPTLMNAL3MBTL1
SCHEMBL10344790 0.86 L3MBTL1 (0.58) MAOBMAOANPC1RAB9ANR4A2
SCHEMBL21991875 0.86 NR4A2 (0.58) MAOBMAOANPC1RAB9ANR4A2
SCHEMBL21991255 0.86 L3MBTL1 (0.58) MAOBMAOANPC1RAB9ANR4A2
SCHEMBL21991595 0.84 MAOB (0.55) MAOBMAOANPC1RAB9ANR4A2
SCHEMBL21991291 0.84 MAOB (0.57) MAOBFFAR1
SCHEMBL21992627 0.83 L3MBTL1 (0.46) ALDH1A1MAPTL3MBTL1MEN1KMT2A
SCHEMBL21991520 0.82 L3MBTL1 (0.52) NPC1RAB9AALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 US disclosed
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MAOB 3946/4885MAOA 3996/4885NPC1 233/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 MAOB 3946/4885MAOA 3996/4885NPC1 233/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MAOB 3946/4885MAOA 3996/4885NPC1 233/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 MAOB 3946/4885MAOA 3996/4885NPC1 233/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 MAOB 3946/4885MAOA 3996/4885NPC1 233/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MAOB 3946/4885MAOA 3996/4885NPC1 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.